BIO-TECHNE (NASDAQ:TECH) and Mymetics (OTCMKTS:MYMX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for BIO-TECHNE and Mymetics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIO-TECHNE 0 2 3 0 2.60
Mymetics 0 0 0 0 N/A

BIO-TECHNE currently has a consensus target price of $204.80, suggesting a potential upside of 3.66%. Given BIO-TECHNE’s higher possible upside, research analysts clearly believe BIO-TECHNE is more favorable than Mymetics.


BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.6%. Mymetics does not pay a dividend. BIO-TECHNE pays out 33.7% of its earnings in the form of a dividend.

Insider and Institutional Ownership

92.1% of BIO-TECHNE shares are held by institutional investors. 3.8% of BIO-TECHNE shares are held by insiders. Comparatively, 54.2% of Mymetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares BIO-TECHNE and Mymetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIO-TECHNE 13.45% 13.20% 7.98%
Mymetics -425.24% N/A -59.28%

Valuation & Earnings

This table compares BIO-TECHNE and Mymetics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BIO-TECHNE $714.01 million 10.48 $96.07 million $3.80 51.99
Mymetics $1.14 million 10.92 -$4.93 million N/A N/A

BIO-TECHNE has higher revenue and earnings than Mymetics.

Volatility & Risk

BIO-TECHNE has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Mymetics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500.


BIO-TECHNE beats Mymetics on 10 of the 13 factors compared between the two stocks.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Mymetics Company Profile

Mymetics Corporation, a vaccine company, focuses on developing vaccines for infectious diseases primarily in Switzerland. The company's product pipeline includes vaccine candidates, such as HIV-1/AIDS, intra nasal influenza, malaria, chikungunya, herpes simplex virus, and the respiratory syncitial virus (RSV) vaccine. It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative; the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; RSV Corporation for developing the RSV vaccine; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with's FREE daily email newsletter.